Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) has shared an announcement.
Haleon PLC has completed the final tranche of its share buyback programme, purchasing 1,561,229 ordinary shares to be held as treasury shares. This move finalizes a series of buybacks initiated earlier in the year, which included shares repurchased from Pfizer, totaling 175,806,525 shares. The completion of this programme is a strategic step for Haleon, impacting its capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow management. However, technical indicators and valuation suggest a more cautious outlook. The earnings call highlighted regional strengths but also significant challenges in North America, impacting the overall sentiment. The absence of notable corporate events leaves the focus on financial and operational performance.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands, such as Advil, Centrum, and Sensodyne, are based on trusted science and innovation.
Average Trading Volume: 20,248,265
Technical Sentiment Signal: Sell
Current Market Cap: £29.45B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.